A GLYCOPROTEIN E (gE) deleted strain of bovine herpesvirus I (BHV-1) provides the basis for efficacious and safe attenuated and inactivated marker vaccines (Kaashoek and others 1994, Bosch and others 1996). Use of these vaccines in the Dutch BHV-I eradication programme will be compulsory commencing in 1998. The companion diagnostic test to differentiate between infected and vaccinated cattle is a blocking ELISA that detects only antibodies directed against gE of BHV-1. Hence antibodies against wild-type BHV-1 and conventional non-gE deleted whole BHV-1 vaccines are detected, whereas antibodies against the gE-deleted marker vaccine are not (Van Oirschot and others 1997 (Kaashoek 1995) .
A GLYCOPROTEIN E (gE) deleted strain of bovine herpesvirus I (BHV-1) provides the basis for efficacious and safe attenuated and inactivated marker vaccines (Kaashoek and others 1994, Bosch and others 1996) . Use (Kaashoek 1995) . The testing of bulk milk has been shown to be of value in screening herds for bovine brucellosis (Knosel and others 1991) and in estimating the prevalence of BHV-1 (Hartman and others 1997, Van Wuijckhuise and others 1998). The aim of this study was to examine whether the BHV-i-gE ELISA is suitable for detecting antibodies directed against BHV-1 in bulk milk, and whether testing of bulk milk could give an indication of the percentage of infected animals in unvaccinated herds and in herds that were vaccinated with the marker vaccine.
To evaluate the specificity of the BHV-i-gE ELISA, Danish negative bulk milk samples were collected from 500 randomly chosen BHV-i-free herds. These freeze-dried bulk milk samples were dissolved in 1 0 ml of deionised water and analysed undiluted in the BHV-i-gE ELISA and in the BHV-i-gB ELISA, To evaluate the sensitivity of the BHV-i-gE ELISA, Dutch bulk milk samples were collected from unvaccinated herds with a BHV-I history, and from herds with a BHV-I history that had been vaccinated three times with the attenuated gE-deleted marker vaccine. The bulk milk samples obtained from vaccinated herds were collected five to six months after the third vaccination. All the herds had participated in a field trial for vaccine efficacy where they were randomly assigned to either an unvaccinated placebo group or to a vaccine group. From each unvaccinated (n = 35) and vaccinated herd (n = 34) one bulk milk sample was collected. On the same day as bulk milk samples were collected, individual serum samples (n = 4297) were collected from all animals older than two years, including those that were dry. The bulk milk samples collected from unvaccinated herds were analysed undiluted in the BHV-1-gE ELISA and the BHV-1-gB ELISA. The bulk milk samples collected from vaccinated herds were analysed undiluted in the BHV-i-gE ELISA only. All bulk milk samples were analysed without concentrating the immunoglobulin fraction as described by Von Forschner and others (1986) . The concentration of bulk milk is too laborious for routine screening (Frankena and others 1997) . The serum samples were analysed in a 1/2 dilution in the BHV-i-gE ELISA according to the instructions of the manufacturer. The blocking percentages of the bulk milk samples were plotted against the percentages of BHV-1-gE-seropositive cattle per unvaccinated (Fig  1) or per vaccinated herd (Fig 2) . In the unvaccinated herds, three bulk milk samples scored negative in the BHV-i-gE ELISA. In these unvaccinated herds five (6 per cent), three (5 per cent) and two (3 per cent) animals were seropositive in the BHV-i-gE ELISA (Fig 1) . The same three, and two other herds from the unvaccinated group, scored negative in the BHV-i-gB ELISA. These latter two herds had eight (16 per cent) and six (12 per cent) animals with BHV-i-gE-seropositive results. Based on these results the BHV-l-gE ELISA had a relative sensitivity of 100 per cent in comparison with the BHV-i-gB ELISA. In the vaccinated herds five bulk milk samples were negative in the BHV-i-gE ELISA. In these vaccinated herds five (10 per cent), five (7 per cent), one (3 per cent), four (13 per cent) and four (8 per cent) animals were seropositive in the BHV-i-gE ELISA (Fig 2) . Overall, the BHV-i-gE ELISA detected antibodies in 88-4 per cent of the bulk milk samples (n = 69) originating from BHV-1 positive herds. There was no difference between the blocking percentages in bulk milk from unvaccinated and vaccinated herds, indicating that antibodies produced against the vaccine strain probably did not have any enhancing effect on the blocking percentages in the BHVi-gE ELISA, as suggested earlier (Van Oirschot and others 1997).
In conclusion, the data in this study demonstrate that the BHV-1-gE ELISA iS suitable to detect BHV-i-gE antibodies in bulk milk samples, and that the transition from a 'negative' to a 'positive' result for bulk milk samples takes place when 10 to 15 per cent of the animals within a herd become BHV-i-gE seropositive. This means that in a BHV-i-eradication programme, the BHV-i-gE ELISA, which detects gE-specific antibodies against wild-type BHV-1 and non-gE deleted whole BHV-1 vaccines, can be used for the screening of bulk milk samples to estimate the prevalence of BHV-1-infected cattle in unvaccinated and vaccinated herds. In the situation that the bulk milk sample is strongly positive in the BHV-l-gE ELISA, vaccination of the herd with a marker vaccine should be recommended. In case the bulk milk sample becomes negative in the BHV-i-gE ELISA, all individual animals should be screened to remove the BHV-i-gE seropositive animals and cessation of vaccination can be considered. Monitoring the bulk milk of BHV-1 free (vaccinated) herds with the BHV-i-gE ELISA with the aim of detecting the introduction of a single or a few BHV-i-infected cattle is, according to these data, not feasible. The same conclusion has been drawn for the BHV-i-gB ELISA (Frankena and others 1997 
